Quarterly Report Q3 2016
Oslo, 11 November 2016 – Navamedic ASA (OSE: NAVA), reported revenues of NOK 65.2 million in the third quarter of 2016 (NOK 61.5 million in Q3 2015), and an EBITDA of NOK 1.8 million (NOK 1.5 million in Q3 2015). The company initiated the long-term strategic partnership with TopRidge Pharma. in the period, with the distribution of Imdur® commencing in the Nordic Markets. The development and commercialisation of Sippi® continues to be on-track.
Gennembrud i dansk depressionsbehandling:
Ny behandling klar til patienter med refraktær depression
Navamedic: Launches treatment device for refractory depression
Oslo, 28 October 2016 – Navamedic ASA (OSE: NAVA), today announced an exclusive agreement with the Danish company, Re5 ApS, for Nordic distribution of Re5-NTS®, an innovative, non-invasive treatment device based on patented Danish technology, for patients with refractory depression.
Commences distribution of Imdur® in Europe
Oslo, 22 September 16 2016 – Navamedic ASA (Navamedic), the Norwegian medtech and pharmaceutical products company, today announced it has commenced distribution of angina prevention medicine, Imdur® (isosorbide mononitrate), in the Nordic markets. The initiation of the distribution is the first step in the long-term strategic partnership with TopRidge Pharma Limited (TopRidge Pharma).
Quarterly Report Q2 2016
Navamedic ASA Quarterly report for Q2 2016